All In MedTech

Device Trial Radar · NCT07934407

HBOT for Perianal Crohn's Disease

Hyperbaric Oxygen Therapy (HBOT) for Refractory Crohn's Perianal Fistulae: a Prospective Interventional Pilot Study

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

10

Planned (sponsor's estimate)

Start

Jul 1, 2027

Primary completion

Apr 1, 2028

Study completion Jun 1, 2028

Sponsor

Lead sponsor
Barts & The London NHS TrustAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 13, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Background Perianal fistulae are among the most disabling complications of Crohn's disease, causing significant morbidity, impaired quality of life, and substantial healthcare utilisation. Despite advances in biologic and surgical therapies, many patients experience persistent fistula drainage and fail to achieve durable healing. Tissue hypoxia is a key regulator of intestinal inflammation and impaired wound healing in inflammatory bowel disease. Hyperbaric oxygen therapy (HBOT) increases tissue oxygenation, promotes angiogenesis, modulates inflammatory pathways, and may enhance fistula healing. Preliminary studies suggest that HBOT is a safe and effective adjunctive treatment for refractory perianal Crohn's fistulae, with reported clinical response rates of 75-87% and remission rates of 50-60%. However, current evidence is limited by small sample sizes and the absence of prospective studies within UK clinical practice. Aim To evaluate the preliminary efficacy of HBOT in patients with refractory perianal Crohn's fistulae treated in an outpatient setting. Methods This prospective pilot study will recruit ten adults with refractory perianal Crohn's fistulae from the Inflammatory Bowel Disease service at Barts Health NHS Trust. Refractory disease will be defined as persistent fistula drainage or failure to heal despite optimised medical therapy and appropriate surgical management. Participants will undergo HBOT 100% oxygen at 2.4 ATA for approximately 90 minutes per session, 40 sessions over 8 weeks. The primary outcome will be overall clinical response, defined as either clinical remission (complete cessation of fistula drainage) or partial response (clinically meaningful reduction in drainage and symptoms). Secondary outcomes will include treatment adherence, safety, tolerability, patient acceptability, and feasibility of recruitment and study completion. Expected Impact This pilot study will generate preliminary efficacy and feasibility data to inform the design, outcome measures, and sample size calculations of a larger clinical trial evaluating HBOT as a novel treatment strategy for refractory perianal Crohn's disease in the United Kingdom.

Conditions

  • Perianal Crohn Disease

Interventions

  • Hyperbaric Oxygen Therapy (HBOT)Device

    Participants with refractory perianal Crohn's disease fistulae will receive hyperbaric oxygen therapy (HBOT) in addition to standard medical care. HBOT consists of 40 treatment sessions delivered over approximately 8 weeks, with participants breathing 100% oxygen at 2.4 atmospheres absolute (ATA) for approximately 90 minutes per session in a multiplace hyperbaric chamber

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical Response of Perianal Crohn's Disease FistulaeTime frame: 16 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Whipps Cross University Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.